• Mashup Score: 0
    MRD: Revolutionizing Lymphoma Care - [2023 SLIDES] - 7 month(s) ago

    By: Allen Wilbanks Date: September 27,2023 In a recent presentation, Elizabeth Brem, MD shared her perspective on the utilization of minimal residual disease (MRD) technology in clinical trials and its potential to transform patient care. She emphasized the various applications of MRD, including its role in gui…

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Revolutionizing Lymphoma Care with MRD Technology. 🔬 @DrLizBrem 's insights on #MRD tech are revolutionizing #Lymphoma care! From CLL to CNS lymphoma, MRD is reshaping treatments.🚀 [video] https://t.co/C6oai2XAjV @_MDEducation @Ryan_Fitzpatric @UCIrvineHealth @HarvardMed https://t.co/k9t4x9qi0x

  • Mashup Score: 1
    Making MRD Assessment Work for AML | ASH Clinical News | American Society of Hematology - 8 month(s) ago

    Leah Lawrence is a freelance health writer and editor based in Delaware. Assessment of measurable residual disease (MRD) is more challenging and difficult to perform in acute myeloid leukemia (AML) than in chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL). The concept of MRD is the evolution of how clinicians try to measure and understand responses to therapy, explained Christopher Hourigan, DM, DPhil, a senior investigator at the National Heart, Lung, and Blood Institute of the

    Source: ashpublications.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASHClinicalNews
      ASHClinicalNews

      #MRD has become an essential prognostic tool for certain #hematologic #malignancies, but its use in #AML still lags behind. However, recent advances in technology and research are bringing the goal of widespread assessment of MRD in AML closer: https://t.co/oy3lxdachS

  • Mashup Score: 1
    ASH Clinical News: September 2023 From the Desk Of... - 8 month(s) ago

    Editor-in-Chief Aaron Gerds, MD, previews the forthcoming September 2023 issue of ASH Clinical News. Highlights include a feature article on the development …

    Source: www.youtube.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASHClinicalNews
      ASHClinicalNews

      See what's to come in the September issue of ASH Clinical News! @AaronGerds shares issue highlights, including a feature article on the use of #MRD testing for #AML, a review of @MikkaelSekeres's "Drugs and the #FDA," and more 🩸 https://t.co/JIzbZiJRBB

  • Mashup Score: 0
    Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia - 9 month(s) ago

    In this review, we discuss the use of measurable residual disease (MRD) in AML, ALL, and chronic myeloid leukemia (CML). Our aims were to review the different methodologies for MRD assessment; describe the clinical relevance and medical decision making on the basis of MRD; compare and contrast the usage of MRD across AML, ALL, and CML; and discuss what patients need to know about MRD as it relates to their disease status and treatment. Finally, we discuss ongoing challenges and future directions with the goal of optimizing MRD usage in leukemia management.

    Source: ascopubs.org
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of ASCO
      ASCO

      Learn more about the use of #MRD to optimize management of #AML, #ALL, and #CML by checking out our new #ASCOEdBook review on this emerging topic! https://t.co/DzJZYIgY9H #ASCO #LEUSM @DrSimoneDekker #ASCO23 https://t.co/4pxMSTyzLc

  • Mashup Score: 1
    Benefits of HSCT for Patients With AML With MRD After Initial Therapy - 11 month(s) ago

    At the 2023 Great Debates & Updates in Hematologic Malignancies meeting in New York, New York, Andrew Artz, MD, participated in a debate about the benefits of hematopoietic stem cell transplantation among patients with AML with MRD after initial therapy.

    Source: HMP Global Learning Network
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLearnNetwork
      OncLearnNetwork

      In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies #GDUHem meeting, Andrew Artz, MD, highlighted the benefits of #HSCT among patients with #AML with #MRD after initial therapy. Learn more: https://t.co/bYy1IL5tcT… @GreatDebatesCME @cityofhope https://t.co/SwwPTzf7ga

  • Mashup Score: 0
    Considering MRD Before HSCT for Patients With Acute Myeloid Leukemia - 11 month(s) ago

    At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, Richard Stone, MD, debated the role of measurable residual disease when considering hematopoietic stem cell transplantation for patients with acute myeloid leukemia.

    Source: HMP Global Learning Network
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLearnNetwork
      OncLearnNetwork

      In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies #GDUHem meeting, Richard Stone, MD, discussed the role of #MRD when considering #HSCT for patients with #AML. Follow along as he shares his insights! https://t.co/tEPPqkhfge… @GreatDebatesCME @DanaFarber https://t.co/vYp7HN2MgQ

Load More